癌症研究
肿瘤微环境
免疫疗法
免疫系统
癌症免疫疗法
化学
肝细胞癌
T细胞
趋化因子
CXCL10型
渗透(HVAC)
细胞
CXCL11型
阿替唑单抗
激活剂(遗传学)
体外
癌细胞
黑色素瘤
车站3
细胞生物学
转录因子
抗体
细胞培养
生物
作者
Deyu Zhang,Dongxin Peng,Xin Wang,Yuting Gao,Zhuang Liu,Rui Yang,Ting Wei,Chengkun Li,Cong Gao,Zhixin Jiang,Hongkun Miao,Pengyun Li,Xingshun Qi
出处
期刊:ACS Nano
[American Chemical Society]
日期:2026-10-24
卷期号:20 (44): 29435-29455
标识
DOI:10.1021/acsnano.6c05553
摘要
The infiltration of CD8+ T cells into the hepatocellular carcinoma (HCC) microenvironment is a well-established determinant of immunotherapy efficacy and patient prognosis. However, the regulatory mechanisms governing this process and the therapeutic strategies capable of modulating it remain largely unexplored. Here, we identify HCC-IN-247 as a candidate compound that enhances IFNβ-driven CD8+ T cell infiltration both in vitro and in vivo. Mechanistic investigations reveal that the long noncoding RNA LINC02084 directly interacts with the transcription factor GLIS1 and facilitates its recruitment to the IFNβ promoter. HCC-IN-247 was identified through screening to target the LINC02084-GLIS1 binding interface, thereby stabilizing this RNA-protein complex. Stabilization of the complex significantly enhances IFNβ transcription, which in turn upregulates CXCL10 and CXCL11 expression and promotes CD8+ T cell infiltration. Furthermore, this study engineered a nanoparticle-based delivery system, designated Lip@RA@BSA-PD-L1/IN-247, for the codelivery of HCC-IN-247 and the anti-PD-L1 antibody atezolizumab in HCC treatment. These nanoparticles exhibited robust tumor-specific accumulation and elicited potent synergistic antitumor activity against HCC in mice. Collectively, our findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI